Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes

Cardiovascular Research

Volumn 32, Issue 3, 1996, Pages 587-592

  Ruiz Meana, Marisol ^a   Garcia Dorado, David ^a   Juliá, Margarita ^a   González, Miguel A ^a   Inserte, Javier ^a   Soler Soler, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cell viability; Cytoskeleton; Myocardial infarction; Myocardial ischemia; Osmotic swelling; Reoxygenation; Reperfusion; Sarcolemma

Indexed keywords

TRIMETAZIDINE;

ADOLESCENT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SARCOLEMMA;

ANIMALS; CELLS, CULTURED; HEART; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OSMOTIC PRESSURE; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; SARCOLEMMA; STRESS, MECHANICAL; TRIMETAZIDINE; VIDEO RECORDING;

EID: 0030248173     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00112-5     Document Type: Article

References (28)

1. [1] Ganote CE, Van der Heide RS. Irreversible injury of isolated adult rat myocytes: osmotic fragility during metabolic inhibition. Am J Pathol 1988;132:212-222.
2. [2] Steenbergen CH, Hill ML, Jennings RB. Volume regulation and plasma membrane injury in aerobic, anaerobic and ischemic myocardium in vitro. Circ Res 1985;57:864-875.
3. [3] Ruiz-Meana M, Garcia-Dorado D, González MA, Barrabés JA, Soler-Soler J. Effect of osmotic stress on sarcolemmal integrity of isolated cardiomyocytes following transient metabolic inhibition. Cardiovasc Res 1995;30:64-69.
4. [4] Siegmund B, Klietz T, Schwartz P, Piper HM. Temporary contractile blockade prevents hypercontracture in anoxic-reoxygenated cardiomyocytes. Am J Physiol 1991;260:H426-435.
5. [5] Garcia-Dorado D, Théroux P, Duran JM, et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 1992;85(3):1160-1174.
6. [6] Steenbergen C, Hill ML, Jennings RB. Cytoskeletal damage during myocardial ischemia: changes in vinculin immunofluorescence staining during total in vitro ischemia in canine heart. Circ Res 1987;60:478-486.
7. [7] Ganote C, Armstrong S. Ischaemia and the myocyte cytoskeleton: review and speculation. Cardiovasc Res 1993;27:1387-1403.
8. [8] Schlüter KD, Jakob G, Ruiz-Meana M, Garcia-Dorado D, Piper HM. Protection of reoxygenated cardiomyocytes against osmotic fragility by NO donors. Am J Physiol 1996(in press).
9. [9] Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989;6:292-312.
10. [10] Belcher P, Drake-Holland AJ, Hynd JW, Noble MIM. Trimetazidine reduces myocardial infarct size, relative area at risk, after temporary coronary artery occlusion in the rabbit. Br J Pharmacol 1992;107:265P.
11. [11] Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of Trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cel Cardiol 1994;26:946-958.
12. [12] Devynck MA, Le Quan Sang KH, Joulin Y, Mazeaud M. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol 1993;245:105-110.
13. [13] Piper HM, Probst I, Schwartz P, Hütter JF, Spieckermann PG. Culturing of calcium stable adult cardiac myocytes. J Mol Cell Cardiol 1982;14:397-412.
14. [14] Altshuld RA, Hostelter JR, Brierley GP. Response of isolated rat heart cells to hypoxia, reoxygenation and acidosis. Circ Res 1981;49:307-316.
15. 2+, ATP and compartmentation. Circ Res 1981;49:1119-1128.
16. [16] Lambert MR, Johnson JD, Lamka KG, Brierley GP, Altshuld RA. Intracellular free calcium and the hypercontracture of adult rat heart myocytes. Arch Biochem Biophys 1986;245:426-435.
17. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286:97-110.
18. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988;1:677-686.
19. [19] Maridonneau-Parini K, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-151.
20. [20] Boucher F, Hearse DJ, Opie L. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 1994;24:45-49.
21. [21] Bowers KC, Allshire AP, Cobbold PH. Continuous measurement of cytoplasmic ATP in single cardiomyocytes during simulation of the 'oxygen paradox'. Cardiovasc Res 1993;27:1831-1839.
22. [22] Verkley AJ, Post JA. Physico-chemical properties and organization of lipids in membranes: their possible role in myocardial injury. Basic Res Cardiol 1987;82(suppl 1):85-91.
23. [23] Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochem Pharmacol 1988;37:4685.
24. [24] Guarnieri C, Muscari C, Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993;46:324-331.
25. [25] Siegmund B, Koop A, Klietz T, Schwartz P, Piper HM. Sarcolemmal integrity and metabolic competence of cardiomyocytes under anoxia-reoxygenation. Am J Physiol 1990;258:H285-H291.
26. [26] Ganote CE. Cell to cell interactions contributing to the 'oxygen paradox'. Basic Res Cardiol 1985;80(suppl 2):141-146.
27. [27] Garcia-Dorado D. Théroux P, Muñoz R, et al. Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size. Am J Physiol 1992;262:H17-H22.
28. [28] Kloner RA, Reimer KA, Willerson JT, Jennings RB. Reduction of experimental myocardial infarct size with hyperosmotic mannitol. Proc Soc Exp Biol Med 1976;151:677-683.